TNF - α Gene Polymorphism is Likely to be a Risk Factor for NASH in Indonesia by Purnomo, Hery Djagat et al.
101 
 
 
TNF - α Gene Polymorphism is Likely to be a Risk 
Factor for NASH in Indonesia 
 
Hery Djagat PURNOMO1*), Farmaditya EP MUNDHOFIR2), KASNO3), Edi SUDIJANTO4), 
DARMONO5), DALDIYONO6), Sultana MH FARADZ2) 
 
1) Division of Gastroenterohepatology Department of Internal Medicine, Dr Kariadi Hospital/ Faculty of 
Medicine Diponegoro University, Semarang, Indonesia 
2) Center for Biomedical Research, Faculty of Medicine Diponegoro University Semarang, Indonesia 
3) Department of Pathology Faculty of Medicine Diponegoro University / Dr.Kariadi Hospital, Semarang, 
Indonesia 
4) Department of Radiology Faculty of Medicine Dr Kariadi Hospital / Diponegoro University, Semarang, 
Indonesia 
5) Division of Endocrinology Departement of Internal Medicine, Faculty of Medicine Diponegoro 
University/ Dr. Kariadi Hospital, Semarang, Indonesia 
6) Division of Gastroenterology Department of Internal Medicine, Faculty of Medicine University of 
Indonesia/ Dr.Cipto Mangunkusumo Hospital, Jakarta, Indonesia 
 
 ABSTRACT  
Introduction : Non alcoholic steatohepatitis  (NASH) is a subset spectrum of  NAFLD that 
can progress toward cirrhosis. Tumor necrosis factor- α (TNF- α) polymorphism play a significant 
role in liver inflammation and Insulin resistance its pathophysiological hallmark. The 
association between TNF- α (-238 and -308) polymorphism) and the severity of NAFLD was 
evaluated. Method: A total of 155 subjects (80 NAFLD cases and 75 controls) were included. 
Liver biopsy was performed for evaluated severity of NAFLD based on NAFLD Activity Score-
CRN in all cases. Controls subjects defined was not any liver disease by ultrasound. Plasma 
TNF– α was measured in all subjects. Polymorphism of` TNF- α promoter gene -308 and -238 
were identified using PCR-RFLP confirmed with direct sequencing.  Results: Liver biopsy 
established the diagnosis of NASH in 29 cases. There was no association between the incidence 
of NAFLD with TNF- α polymorphism at the TNF– α -308 or the -238 (p>0.05). The prevalence 
ratio of TNF– α polymorphism -238 was significantly higher for subject with NASH (p< 0.02). 
There was no different prevalence ratio for TNF– α polymorphism -308 (p>0,05). We found novel 
polymorphism of TNF- α -245 T/C in a subject with possible NASH, high plasma TNF- α level 
(20.27 pg/cc) and very high value of Homeostasis Model of Assessment - Insulin Resistance 
HOMA-IR (22.73).  Conclusion : Polymorphism TNF- α -238 is likely to be a risk factor for 
NASH in Indonesia. The identification of new possible polymorphism of TNF- α -245 requires 
further study in more samples. 
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INTRODUCTION 
Non Alcoholic Steatohepatitis (NASH) is the 
most severe form of Non Alcoholic Fatty Liver 
Disease (NAFLD). NASH is clinically a 
manifestation of chronic liver disease frequently  
occur in industrial countries and its rate has been 
increasing in developing countries (1). Recent 
epidemiology study (2010) in Asia, Europe, 
Middle East, North and South  America stated the 
prevalence of NAFLD ranging from 6-35% with 
median 20%(2). Hasan Irsan reported that NAFLD 
was found in 30% of the population in Jakarta 
based on abdominal ultrasound (3).  
Tumor Necrosis Factor (TNF)-α polymorphism 
has been reported to have effect on the 
susceptibility of several liver diseases including 
NASH and more scientific proof showed the 
involvement of TNF-α in the pathogenesis and 
progression of liver disease caused by many 
etiologies (4, 5). Data from several clinical and 
experimental studies revealed TNF-α played roles 
not only in early stage of fatty liver disease but 
also in transition process to more advanced liver 
damage. The role of TNF-α in NAFLD is a 
crossroad of pathogenic pathway. Major 
difference between patients with simple steatosis 
and NASH is that serum level of TNF-α  is found 
higher in NASH even though the result did not 
always reach statistical significance (6).      
Two polymorphisms in TNF-α gene promoter 
have been identified: at position 308 (TNF2 allele) 
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and at position 238 (allele TNFA). Studies on the 
allele TNF-α proved the increased formation and 
expression of these cytokines compared to the 
wild type (TNF-1), although the reported data of 
TNF- α allele was conflicting, but many 
researchers believed that TNF- α allele increases 
the release of this cytokine (7). 
Luca Valenti (2002) in his research revealed 
genes that influence the effect of TNF-α , that is 
polymorphism in gene promoter -238 that 
correlates well with alcoholic steatohepatitis or 
NASH(4). Katsutoshi T (2007) reported that 
serum level of TNF-α was higher in NASH 
patients than that of steatosis and normal 
patients. There was no significant deviation in the 
analysis of TNF-α gene polymorphism between all 
groups. The number of gene promoter -1031C and 
-863A in patients with NASH was higher than 
that of simple steatosis group. Multivariate 
analysis has proven that polymorphism is an 
independent factor which differentiate NASH 
from from simple steatosis. It was concluded that 
TNF-α  polymorphism influences TNF-α  
production and correlates with the progression of 
NAFLD (8). However, data from several studies 
were conflicting that further study is needed to 
confirm its correlation.  
 
MATERIAL AND METHODS 
A case-control study held in outpatient clinic of 
dr. Kariadi General Hospital Semarang on 
January 2009 – December 2011.  
Inclusion criteria for case group includes: aged 
> 14 years old having metabolic syndrome 
components and proven to have NAFLD based on 
abdominal ultrasound. Subjects will be excluded 
if known to have hepatitis A, B, C virus infection 
(AST and ALT > 5 times higher than normal with 
positive IgM anti HAV or positive HBsAg or 
positive anti HCV); autoimmune hepatitis 
(positive ANA test); alcoholic hepatitis; history of 
alcohol consumption (> 30 gr/ day for male and > 
20 gr/day fpr female); history of taking drugs 
causing fatty liver (glucocorticoid, estrogen, 
tamoxifen, amiodarone, metothrexate, valproate, 
diltiazem).  
Inclusion criteria for control group includes no 
history, and clinical symptoms of liver disease 
(with normal AST and ALT, negative HbsAg, 
negative anti HCV) and no liver abnormality 
found on abdominal ultrasound. Subjects will 
excluded if known to have liver disease by 
anamnesis, physical examination and laboratory 
findings; hepatitis virus infection (A,B,C); 
autoimmune hepatitits, alcoholic hepatitis; 
history of alcohol consumption; and history of 
taking drugs causing fatty liver.  
All subjects underwent these following physical 
and laboratory examinations: blood pressure, 
body weight, height, body mass index, waist 
circumference, liver enzymes (AST, ALT), lipid 
profile (HDL, total cholesterole, triglyceride) and 
fasting blood glucose. Serum level of TNF-α was 
tested in all subjects of case and control groups. 
Liver biopsy was performed only in NAFLD 
subjects for classification of severity by Kleiner et 
al; NASH Clinical research network scoring 
system (NAFLD activity score =NAS). NASH was 
defined if NAS > 5, Possible NASH if NAS 3-4 and 
Simple steatosis if NAS < 3 consecutively. TNF-α 
polymorphism in gene promoter -238 and -308 
was tested using Polymerase Chain Reaction- 
Restriction Fragment Length Polymorphism 
(PCR-RFLP) and confirmed by direct sequencing.   
 
RESULTS 
Basic Characteristics 
During study period, 150 subjects were enrolled 
and divided into 2 groups. Case group (n=75) 
consisted of NAFLD patients and control group 
(n=75) consisted of healthy subejcts without fatty 
liver. The clinical characteristics of all subjects in 
both groups are shown in table 1. 
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Table 1. Clinical characteristics, serum level of TNF-α and gene promoter polymorphism 
of subjects in case and control group 
Characteristic 
Group 
p 
Case (n=75) Control (n=75) 
Sex α   
< 0,100* 
Male 45 (55,6%) 36 (44,4%) 
- Female 30 (43,5%) 39 (56,5%) 
Age (year)£ 44,7 ±10,28  
(23,0 - 74,0) 
44,3 ± 9,98 
(20,0 - 72,0) < 0,800§ 
Male age (year)£ 42,6 ±10,36 
(25,0 - 74,0) 
42,0 ± 11,04  
(20,0 - 72,0)  < 0,800§ 
Female age (year)£ 48,0 ± 9,42 
(25,0 74,0) 
46,5 ± 8,47  
(26,0 - 63,0)  < 0,500§ 
Body weight (kg)$ 77,0 (54,0 - 115,0)  56,0 (41,0 - 74,0)  < 0,001¶ 
Height (cm)£ 162,1±8,37  
(140 – 178) 
161,1±6,31 
(147,0 - 179,0) < 0,400§ 
Body mass index $ 29,0  (22,0 -  47,4) 22,5 (17,3 - 27,5) < 0,001¶ 
Waist circumference (cm)$ 
TNF-α  (pg/ml) $ 
TNF-α (pg/ml) >3,645 
                           3,645 
TNF-α gene promoter 
polymorphism 
Region-238 
             G/G 
             A/G 
             A/A 
         Frequency alel A (%) 
Region-308 
             G/G 
             A/G 
             A/A 
         Frequency alele A(%) 
99,0  (77,0 - 134,0) 
7,98 (0,00-332,56) 
58 (76,3%) 
17 (23,0%) 
 
 
 
72(96,0%) 
3 (4,0%) 
0 (0,0%) 
2,0 
 
74(98,7%) 
1(1,3%) 
0(0,0) 
0,7 
80,0  (64,0 - 98,0) 
2,24 (0,04-77,65) 
18 (23,7%) 
57 (77,0%) 
 
 
 
73 (97,3%) 
2 (2,7%) 
0 (0,0%) 
1,3 
 
72(96,0%)                    
3(4,0%) 
0(0,0) 
2 
< 0,001¶ 
<0,001¶ 
 
<0,001* 
 
 
 
 
 
 
0,700  
 
 
    0,600  
£ Mean ± standard deviation (minimum-maximum); $ Median (minimum – maximum) 
*x2 test; §Independent t-test; ¶Mann-Whitney test, zFisher-exact test, Frequency of alele 
A=(frequency of alele A/total alele) x 100% 
Serum level of TNF-α 
Serum level of TNF-α of subjects in case and 
control groups is shown in table 1.  The result 
shows that mean serum level of TNF- α in case 
group was significantly higher than that of control 
group (p<0,001).   
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Cut-off level of TNF- α to diagnose NAFLD 
The result of receiver operating characteristics 
(ROC) analysis for TNF- α to determine the 
incidence of NAFLD. Area under the ROC curve 
of serum level of TNF- α to determine the 
incidence of NAFLD was 0,80 (95% CI=0,73 s/d 
0,87) and it was statistically significant (p<0,001). 
ROC analysis also demonstrated cutoff point for 
serum level of TNF- α to determine the incidence 
of NAFLD was 3,645 ng/ml. Based on the cutoff 
point, further analysis was done. The subjects 
with serum level of TNF- α > 3,645 pg/ml were in 
the case group (76,3%), and on the opposite, 
subjects with TNF- α < 3,645 pg/ml were mostly 
in the control group (77%). Statistical analysis 
confirmed that the significant correlation between 
serum level of TNF- α and the incidence of 
NAFLD.  
 
TNF- α gene promoter 238 dan -308 
polymorphism in NAFLD 
The results of PCR-RFLP investigating TNF-α 
gene promoter -308 G/A and -238 G/A 
polymorphism are visulized in figure 1a and Ib 
 
Results of liver biopsy. 
Liver biopsy is a gold standard for the diagnosis 
of NAFLD severity. Most of the subjects in this 
case group of severity were included in the 
Possible NASH in 38 subjects (50.67%), then 
NASH in 29 subjects (38.67%) and at least the 
Simple Steatosis in 8 subjects (10.67 %). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1b . Agarose gel visualization for TNF-α gene promoter -238 
(PCR-RFLP) polymorphism 
Showing agarose gel as the result of PCR-RFLP  TNF-α regio promoter -238 polymorphism. Size of 
product after RFLwas 77 bp, 63 bp, 49 bp and 21 bp for -238 G/A polymorphism. Size of wildtype -
238 G/G was 77, 70, 63, dan 49 bp. Product sized 70 bp  and 21 bp  were not visualized on agarose 
gel. No allele 2 (-238 A/A) was found 
M G/A G/G 
100 bp 
77 bp 
63 bp 
49 bp 
Figure 1b . Agarose gel visualization for TNF-α gene promoter -238 (PCR-
RFLP) polymorphism 
Showing agarose gel as the result of PCR-RFLP  TNF-α regio promoter -238 polymorphism. Size of 
product after RFLwas 77 bp, 63 bp, 49 bp and 21 bp for -238 G/A polymorphism. Size of wildtype -238 
G/G was 77, 70, 63, dan 49 bp. Product sized 70 bp  and 21 bp  were not visualized on agarose gel. No 
allele 2 (-238 A/A) was found 
M G/A G/G 
100 bp 
77 bp 
63 bp 
49 bp 
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TNF- α gene promoter -238 and -308 
polymorphisms 
TNF- α polymorphism test using PCR-RFLP 
method was confirmed by direct sequencing due 
to very little polymorphism found by the PCR-
RFLP in Indonesian population, or there was 
possibly other kind of univestigated 
polymorphism. Distribution of TNF- α 
polymorphism located in gene promoter -238 and 
-308 is listed in table 1. In table 1, the genotype of 
TNF- α promoter -238 mostly seen in both case 
and control group was G/G. TNF- α -gene 238A/G 
polymorphism was found in 5 subjects (3 in case 
group and 2 in control group). TNF- α   -gene 
238A/A polymorphism was not found. The 
frequency of allele A TNF- α -gene 238 
polymorphism in case group was higher than that 
of control group. Statistical analysis shows no 
significant difference in the incidence of TNF- α -
gene 238A/G polymorphism between case and 
control group (p=0,7).  
In table1, the genotype of TNF- α promoter -308 
mostly seen in both case and control groups was 
G/G. TNF- α -gene 308A/G polymorphism was 
found in 4 subjects (1 in case group and 3 in 
control group). Uncommon allel in control group 
was found more frequent in control group 
compared to case group (typical for Javanese-
Indonesian population). TNF- α   -gene 308A/A 
polymorphism was not found. The frequency of 
allele A TNF- α -gene 308 polymorphism in control 
group was higher than that of case group. 
Statistical analysis shows no significant 
difference in the incidence of TNF- α -gene 308A/G 
polymorphism between case and control group 
(p=0,6).  
 
Serum level of TNF- α based on TNF- α - gene 
238 and -308 polymorphisms 
Table 2 below shows serum level of TNF- α based 
on TNF- α - gene 238 and -308 polymorphisms.
 
 
Table 2. Serum level TNF- α based on genotype of TNF- α -238 and 308 
Promoter region 
Allel  TNF- α 
p¶ 
GG AG 
- TNF- α -238 3,56 (0,00 - 332,56) 22,42 (3,56 - 107,87) 0,020 
- TNF- α -308 3,89 (0,00 - 332,56) 2,36 (1,51 - 31,93) 0,600 
 
$ Median (minimum – maximum) 
¶ Mann-Whitney test 
 
Data on table 2 shows that serum level of TNF- 
α in subjects with TNF- α gene -238A/G 
polymorphism (n=5) has higher level of TNF- α 
than that of without polymorphism (n=145) with 
significant difference (p=0,02). Serum level of 
TNF- α in subjects without TNF- α gene -308 
polymorphism (n=146) has higher level of TNF- α 
than that of with TNF- α -308A/G polymorphism 
(n=4) but the difference was not statistically 
significant (p=0,6).  
 
Distribution of TNF- α gene promoter -238 
and -308 polymorphisms  
TNF- α -gene 238 polymorphisms was found in 5 
subjects (3 NASH and 2 central obesity (-)). There 
was no difference in TNF- α -gene 238 
polymorphisms between groups (p = 0,1). TNF- α 
-gene 308 polymorphisms was found in 4 subjects 
(1 NASH, 2 central obesity (+), 1 central obesity (-
)). There was no difference in TNF-α -gene 308 
polymorphisms between groups (p = 0,1). DNA 
sequencing of TNF- α gene -308 G/A, -238 G/A, -
245 T/C and wild type is picturized in figure 2. 
 
 
 
 
 
 
 
 
TNF - α Gene Polymorphism as a Risk Factor for NASH in Indonesia 
106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. DNA sequencing chromatogram of gene polymorphism and wild type of TNF-α -308, -238, and -245 
 
As seen in figure 2, sequencing chromatogram 
shows the presence of polymorphism (red band) 
(overlapping band/ heterozygote) in TNF- α –gene 
promoter -308 G/A (a), TNF- α -gene promoter -
238 G/A (c), and TNF- α -gene promoter -245 C/T 
(e). Figure b,d and f consecutively are the wild 
type of TNF- α -gene promoter -308, -238 dan -245. 
 
 
Table 3. Risk factor of NAFLD 
Risk factor  
Group 
Odd Ratio (95% 
confidence interval) p* 
Case 
n=75 
n (%) 
Control 
n=75 
n (%) 
TNF- α (pg/mL)     
- > 3,645 58 (76,3%) 18 (23,7%) 10,8 (5,1 s/d 23,0) < 0,001 
- α 3,645  17 (23,0%) 57 (77,0%)   
TNF- α -gene 238A/G 
Polymorphism 
  
  
- Present 3 (60%) 2 (40,0%) 1,5 (0,2 s/d 9,4) 0,700 
- Absent 72 (49,7%) 73 (50,3%)   
TNF- α -gene 308A/G 
Polymorphism 
  
  
- Present 1 (25,0%) 3 (75,0%) 0,3 (0,03 s/d 3,2) 0,600 
- Absent 74 (50,7%) 72 (49,3%)   
* α 2 test 
a) -308 G/A 
Polymorphism  
c) -238 G/A 
Polymorphism 
e) -245 C/T 
polymorphism 
b) -308 wildtype 
d) -238 wildtype 
f) -245 wildtype 
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TNF-α and TNF-α gene polymorphism as 
risk factor of NAFLD 
Analysis of TNF-α level TNF-α gene 
polymorphism as risk factor of NAFLD can be 
seen in table 3 Subjects with serum level of TNF- 
α > 3,645 pg/mL are 10,8 times more likely to 
develop NAFLD compared to those whose level of 
TNF- α   3,645 pg/mL. As listed in table 3, TNF- 
α > 3,645 pg/mL is a risk factor for developing 
NAFLD (p < 0,001). On the other hand, TNF- α 
gene polymorphism was not proven to be risk 
factor of NAFLD. 
 
TNF-α and TNF-α gene polymorphism as 
risk factor of NASH 
Analysis for risk factor of NASH is listed on table 
4. Non NASH group consists of combination of 
subjects with suspected NASH, simple steatosis, 
central obesity (+) and central obesity (-).
 
Table 4 . Analysis for risk factor of  severity of  NAFLD 
Risk factor  
Group 
Prevalence ratio 
(95% confidence 
interval) 
p NASH 
n=29 
n (%) 
Non NASH 
n=126 
n (%) 
TNF- α (pg/mL)     
- > 9,41 18 (39,1%) 28 (60,9%) 3,9  (2,0 s/d 7,5) < 0,001* 
- α 9,41  11 (10,1%) 98 (89,9%)   
TNF- α -gene 238A/G 
Polymorphism 
  
  
   Present 3 (60,0%) 2 (40,0%) 3,5 (1,6 s/d 7,7) 0,020¥ 
   Absent 26 (17,3%) 124 (82,7%)   
TNF- α -gene 308A/G 
Polymorphism 
  
  
   Present 1 (25,0%) 3 (75,0%) 1,3 (0,2 s/d 7,6) 0,700¥ 
   Absent 28 (18,5%) 123 (81,5%)   
* α 2 test              n=75 healthy control by ultrasound, n=80 cases by liver biopsy (Nafld activity 
score)                  
¥ Fisher-exact test  
 
TNF- α -gene 238A/G polymorphism has prevalence ratio 3,5 (1,6 s/d 7,7) which means subjects having TNF- 
α -gene 238A/G polymorphism are 3,5 times more likely to develop NASH compared to those without TNF- 
α -gene 238A/G polymorphism. Based on 95% confidence interval, TNF- α -gene 238A/G polymorphism was 
concluded as risk factor of NASH. TNF- α -gene 308A/G polymorphism was not considered as risk factor of 
NASH based on the analysis despite the prevalence ratio (4, 9) 
 
DISCUSSION 
This study was first performed in Indonesia 
nonalcoholic fatty liver disease patients linked to 
the level TNF- α, severity and polymorphism 
gene. 
Tumor necrosis factor- α is well-known as major 
cytokine that plays important role in the 
occurance of liver damage, including fatty and 
inflammatory liver disease (steatohepatitis) (10, 11). 
Studies investigating about TNF- α gene 
polymorphism in NAFLD have been showing 
conflicting results. Several studies reporting the 
correlation of TNF- α polymorphism and 
susceptibility of NASH(11-14) yet there were also 
other studies not supporting the theory (8, 15). This 
study focused on 2 polymorphisms located in 
region -308 dan -238
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The findings in our  study were 
inconsistent  with previous  studies by 
Valenti et al (2002) and Murillo et al (2011) 
in a population of Mexican and Italian that 
reported gene polymorphism (9, 12, 13, 16). This 
study reported TNF-α -238 as risk factor of 
NASH /severity of NAFLD, whereas TNF-α 
gene polymorphism-308 was not a risk factor 
of NAFLD. In contrast to previous research 
results by Aller et al (2010) in Spanish 
population TNF-α gene polymorphism -308 
was found to be associated with 
histopathologic changes of the liver (13). 
Tokushige (2007) reported in the Japanese 
population polymorphism associated with 
TNF-α increased blood levels of TNF-α (8). 
Additionally Tokushige also reported TNF-α 
gene polymorphism positions -1031, -863 
instead of the -857, -308 and -238 associated 
with progression of NAFLD (incidence of 
NASH)12. The results of the meta-analysis by 
Wang et al (2012) in 7 case-control study 
TNF-α gene polymorphisms and 8 case-
control studies concluded; TNF-α gene 
polymorphism -238 was a risk factor NAFLD, 
whereas gene polymorphism TNF-α-308 was  
not a risk factors NAFLD (17). Murillo at al 
(2011) also reported gene polymorphism 
TNF-α -238 associated with the onset of 
sensitivity NASH (12). 
In accordance to the previous studies, we 
found that serum level of TNF-α is 
significantly higher in subjects with TNF-α 
gene -238 polymorphism compared to those 
without TNF-α gene -238 polymorphism. 
There was no difference in serum level of 
TNF-α between subjects with and without 
TNF-α gene -308 polymorphism. TNF-α gene 
-238 polymorphism is not only related to the 
increase of serum level of TNF-α, but also to 
the occurence of insulin resistance (8). TNF-α 
has been reported to cause trauma and 
apoptosis of liver tissue, play role in netrophil 
chemotactic, activation of stellate cells of the 
liver and related to insulin resistance locally 
in liver tissue or systemically (18). Crespo et 
all (2001) reported significant increase of 
TNF-α expression and receptors in liver and 
increase of TNF-α expression in adipose 
tissue in NAFLD patients with obesity (19).  
Ethnical variety determines the different 
roles of metabolic and sosio-demography risk 
factors in NASH (20), therefore further study 
involving different ethnicity is needed to 
confirm the pathogenesis. This study has 
shown that TNF-α polymorphism in 
Indonesian population (specifically 
Javanese-dominant) is different from 
Kaukasian population. It is suggested to 
conduct a larger study (multicenter) to prove 
that TNF-α gene -238 A/G polymorphism is a 
risk factor of severity of NAFLD (risk factor 
of incidence of NASH) considering the 
significantly high level of TNF-α was found in 
subjects with TNF-α gene -238 
polymorphism.  
This study also found one subject with 2 
(doubles) polymorphisms (haplotypes) that 
have the highest severity of NAFLD (NAS 
score = 7). In addition, it was also found in 
this study 1 subject with novel 
polymorphism, that is TNF- α - 245 T/C with 
clinical characteristics showing high level of 
insulin resistance and very low level of 
adiponectin (1401 ng/cc). Further study with 
a larger sample is suggested to explain better 
the consistency of the relationship. 
The limitation of this study were tools for 
determining the presence of fatty liver in case 
group and the healthy control were not the 
same, liver biopsies were performed only in 
the case group, while the healthy control 
group with ultrasonography, this potentially 
arising the measurement bias. 
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